Zhenhua Wu

Title: Zhenhua Wu and EGFR-Targeted Pharmaceutical Innovation

Introduction

Zhenhua Wu is an inventor associated with Xiamen, China, and Hongyun Biotech Co., Ltd. His listed patent work concerns an alkenyl pyrimidine compound designed to inhibit EGFR, a kinase involved in cancer and other diseases.

Latest Patents

Wu is associated with one patent: “Alkenyl Pyrimidine Compound, Preparation Method Therefor, and Application Thereof.” The invention describes an alkenyl pyrimidine compound, along with pharmaceutically acceptable salts or solvates, methods for preparing it, and a pharmaceutical composition containing it. The patent also describes using the compound to prepare drugs for preventing or treating cancer and other diseases mediated by EGFR kinase. Wu’s listed portfolio includes 1 patent.

Career Highlights

The available information identifies Wu’s work with Hongyun Biotech Co., Ltd. and highlights his contribution to research on compounds with EGFR-inhibitory activity. The patent connects compound development and preparation methods with potential pharmaceutical applications.

Collaborations

Wu’s listed coworkers include Xianming Deng and Wei Huang. Their names are associated with the same professional context, though the provided information does not specify their individual roles in the patent.

Conclusion

Zhenhua Wu’s documented patent work centers on an EGFR-inhibiting alkenyl pyrimidine compound and its potential pharmaceutical applications, reflecting a contribution to drug research at Hongyun Biotech Co., Ltd.